pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. Sarah Rickwood has 30 years’ experience as a consultant to the pharmaceutical industry. appeared first on.

HIV Treatment and Prevention Agents 59

HIV Treatment and Prevention Agents Vaccines Pharmaceutical Companies Pharmaceutical Companies 59

Express Pharma

JULY 10, 2024

India has traced a journey of grit and glory to emerge as a major supplier of generic drugs and vaccines globally. IBER Report 2023 divulges, “The biopharma vaccines (non-COVID alone) market makes a significant daily contribution of approximately $38 million. Today, it is a key player in the global pharma landscape. billion monthly.”

Vaccines 96

Vaccines Drug Development Process Improvement Biosimilars 96

Pharmaceutical Technology

JULY 23, 2008

The world’s biggest pharmaceutical company Pfizer announced in June 2008 that it would be putting its “full scope and scale” behind a push into the cancer market. “Companies used to be universally protected by patents but there is a pathway to approval opening up for biosimilar legislation. .

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Compounding Biosimilars 40

pharmaphorum

JANUARY 5, 2021

One bright spot in an otherwise dreadful year: the pharmaceutical industry has discovered it can do things it never dreamed possible. Anyone who proposed that a novel, deadly virus would spread, with a vaccine developed demonstrating 95% efficacy, and approved for patients in less than a year would have been scoffed at.

Hospitals 105

Hospitals Vaccines Pharmaceutical Companies Pharmaceutical Companies 105

European Pharmaceutical Review

FEBRUARY 26, 2024

Carvykti According to the Janssen Pharmaceutical Companies of Johnson & Johnson, the CHMP recommended cilta-cel as a treatment for adults with relapsed and refractory multiple myeloma (RRMM). CHMP meeting highlights: January 2024 The post CHMP meeting highlights: February 2024 appeared first on European Pharmaceutical Review.

Generic Medicine 98

Generic Medicine Vaccines Pharmaceutical Companies Pharmaceutical Companies 98

pharmaphorum

APRIL 16, 2021

Even with the vaccine roll-out, further waves of COVID infection and lockdowns mean these vital drivers of launch performance remain impacted in 2021, and even beyond. It is also significantly biologic and biosimilars, although a mature market, do not yet yield cost savings as efficiently as small molecule generics do.

Pharmaceutical Companies 95

Pharmaceutical Companies Pharmaceutical Companies Vaccines Documentation 95

Pharmaceutical Technology

SEPTEMBER 26, 2022

The company told GlobalData PharmSource: “The biosimilar facilities in Austria and Slovenia would continue to manufacture biosimilars for Sandoz under a contractual agreement with Novartis. Both Sandoz and Novartis are internationally renowned pharma companies, with a combined 34 production facilities worldwide.

Biosimilars 64

Biosimilars Drug Development Vaccines Dosage 64

pharmaphorum

DECEMBER 2, 2020

In 2015 the company also paid $17 billion to acquire Hospira , a firm specialising in injectable drugs and biosimilars, at a time when copycat biologics were starting to make real waves in the market. AZ seemed to have little interest in the idea, and the deal was instantly controversial in both Europe and the US.

Compounding 128

Compounding Vaccines Biosimilars Diabetes 128

PharmaShots

APRIL 13, 2023

model is a holistic approach to incorporate the same strategy to life science and pharmaceutical companies. A globally fast-growing, and largest pharmaceutical company in the world was created through a merger between Pfizer and Pharmacia. Model: Inspired by the industry 4.0 model, the pharma 4.0 compared to 2015.

Biosimilars 40

Biosimilars Vaccines Pharmaceutical Companies Pharmaceutical Companies 40

Pharmaceutical Technology

DECEMBER 22, 2022

The company has founded a non-commercial Global Health Unit to meet these goals. New vaccines and therapies for the prevention and treatment of malaria, tuberculosis, human immunodeficiency virus (HIV), neglected tropical diseases (NTDs) and anti-microbial resistance (AMR) will be the focus of the research and investment.

Diabetes 52

Diabetes Biosimilars Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

NOVEMBER 10, 2022

We can talk all the time, Montserrat said, but now is the time for action: early diagnosis, access to the best treatments, innovation, in addition to protection of intellectual property (IP), and after that biosimilars and generics. With 90% of adolescents that should be vaccinated by 2030, Luppi deems it an opportunity.

Vaccines 97

Vaccines Biosimilars Labelling Pharmaceutical Companies 97

Big Molecule Watch

MARCH 30, 2023

The new report from the Biden Administration states that “[i]mprovements in human health outcomes have benefited from advances in biotechnology and biomanufacturing over the last two centuries, from the discovery of genetics and the development of early vaccines to modern robotic limbs and engineered cell therapy.”

Biosimilars 49

Biosimilars Pharmaceutical Companies Pharmaceutical Companies Vaccines 49

Pharmaceutical Technology

APRIL 12, 2023

The Association of the British Pharmaceutical Industry (ABPI) also states that “the use of animals in medical research has played and continues to play an essential role in the development of new medicines and vaccines”. The topic of animal testing remains a fiercely contentious topic in the public eye. The FDA’s Modernization Act 2.0

Vaccines 98

Vaccines Biosimilars Communication Pharmaceutical Companies 98

pharmaphorum

JANUARY 22, 2021

.” Generic and opioid-alternative companies could benefit from expanded coverage, if Biden changes policy, according to analysts at Jefferies. COVID has been a global disaster and unfortunately there are other pathogens that can be as or more deadly. ” Science first.

Drug Pricing 63

Drug Pricing Packaging Biosimilars Pharmaceutical Companies 63